Research on psilocybin in the treatment of psychiatric disorders.
Share
Early results show that when psilocybin is used with screening and medical support, it may be more effective in treating some psychiatric disorders than existing treatments and without the need to take medication every day. A single treatment improved symptoms for months.
Dedicated researchers, institutions, and funding are needed to make this groundbreaking research happen. However, the government has not yet funded this research, and pharmaceutical companies see no way to profit from drugs that cannot be patented. These obstacles, in addition to cultural stigma, have slowed progress in this area for decades.
Based on scientific expertise and partnerships with leading researchers worldwide, Heffter also mentors the next generation of psilocybin researchers, examines new approaches, supports proof-of-concept studies, and compiles the evidence base for therapeutic treatments that can help patients in need.
The foundation of Johns Hopkins Center for Psychedelic Research the NYU Center for Psychedelic Medicine , and the beginning of the project of The success of the Usona Institute in obtaining FDA approval for psilocybin for medical treatment is deeply gratifying for everyone at Heffter, having been instrumental in guiding and funding the work that led to these profound institutional developments. The Heffter Research Institute is working to create similar psychedelic research centers at other universities, where it has mentored and funded the development of teams that are now conducting various human trials using psilocybin to assess clinical efficacy for a variety of indications. The Dana-Farber Cancer Institute at Harvard Medical School is about to begin a clinical trial using psilocybin. for palliative care patients. When completed, it will be the first human psychedelic study at Harvard in nearly 60 years, and it is a trial reviewed and funded by Heffter. Yale University is conducting several trials evaluating psilocybin for depression, headache disorders, and OCD, again reviewed and funded by Heffter. We are also investigating basic science regarding mechanisms of action and biomarkers.
Heffter's research informs the public about the beneficial applications of psychedelics for both science and public health. This research provides scientific knowledge that guides scientists toward new experiments to understand the brain and consciousness. Based on Heffter's support for depression and anxiety in cancer patients, the Usona Institute He began his research to make psilocybin treatment available to anyone with depression. Heffter's current clinical trials will provide medical evidence to create new treatments for everyone with addictions and other conditions.